Introduction
Chronic hepatitis C virus (HCV) infection is a major causative agent for severe liver disease and cancer worldwide. Globally, around 185 million individuals are estimated to have anti-HCV antibodies and of these 130-170 millions are chronic carriers of the virus [1, 2] . Importantly, this infection is today considered curable in the majority of individuals receiving the recently introduced direct-acting antiviral (DAA) therapy [3] [4] [5] [6] [7] . Therefore the urgency for a HCV vaccine has reduced. However, only 10% of all chronic HCV carriers receive any treatment [1] due to high cost of treatment and the majority of the chronic carriers live in resource-poor countries. Hence, there is still an urgent need to prevent the spread of HCV through a vaccine. Today, no prophylactic or therapeutic vaccines are available. However, numerous vaccines have been developed and tested for efficacy in clinical trials [8] [9] [10] [11] [12] [13] [14] . A few HCV vaccines are currently being tested for both protective and therapeutic effects [15] [16] [17] .
A key feature of patients with chronic HCV is their lack of functional T cell responses to HCV [18] [19] [20] [21] [22] [23] . Interestingly, a recent study showed that DAA induced cure of HCV rapidly restores at least partly HCV-specific T cell responses [24] . However, these responses do not seem to protect against re-infection [25] . Thus, a therapeutic HCV vaccine would be of importance to support eradication of HCV infection and to broaden the HCV post-cure T cell response to reduce the risk of re-infection. On the other hand, a prophylactic HCV vaccine would instead be crucial in reducing the risk of acquiring HCV, especially since the majority of HCV infected individuals develop an asymptomatic chronic infection that is often first diagnosed at a late stage of the liver disease. A functional prophylactic and/or therapeutic HCV vaccine will save significant costs and reduce HCV associated morbidity and mortality.
We have previously shown that the addition of heterologous gene sequences makes antigen-specific vaccines more effective in the presence of dysfunctional antigen-specific T cell responses [26] . The human hepatitis B core antigen (HBcAg) is a potent molecular adjuvant both as a protein and in genetic vaccines [26] [27] [28] . However, since two billion people have been in contact with HBV, one may question the use of human HBV sequences as adjuvant. We therefore here exploit the use of avian HBcAg sequences as heterologous adjuvant sequences. Notably, human and avian HBcAg show less than 40% amino acid sequence homology and they do not share the same HLA/MHC class I and II epitope sequences. Herein, the avian HBcAg adjuvant sequences were evaluated using our previously clinically evaluated genotype 1 HCV non-structural 3/4A (NS3/4A) based genetic vaccine [8, 29, 30] . We found that avian HBcAg gene sequences significantly improved the DNA-based HCV vaccine.
Methods

Animals
Inbred female C57BL/6J (H-2 b ), CD4-deficient (e.g. CD4−/− (H-2 b )), CD8-deficient (e.g. CD8−/− (H-2 b )), C57BL/6J mice transgenic (Tg) for full-length wild-type HCV nonstructural (NS)3/4A of genotype 1a (NS3/4A-Tg) under the control of the mouse major urinary protein promoter (MUP) [31] , and C57BL/6J mice transgenic for HBeAg subtype ayw under the control of the metallothionein promoter (HBeAg-Tg) [27, [32] [33] [34] , were housed at Karolinska Institutet, Division of Comparative Medicine, Clinical Research Center, Karolinska University Hospital, Huddinge, Sweden. The NS3/4A-Tg and the HBeAg-Tg mouse models were used to assess vaccineprimed immune responses because they better represents a model of an infected host with dysfunctional T cell responses to NS3/4A (NS3/4A-Tg) or to both HBcAg and HBeAg (HBeAg-Tg). Vaccine evaluation in wild-type mice will only address naïve immune responses and is therefore less relevant for studies of chronic infections. The animals were either purchased (Charles River Laboratories, Sulzfeld, Germany and the Jackson Laboratory, Bar Harbor, ME) or bred in-house. The animals were caged at five to ten mice per cage and fed with a commercial diet (RM3 (p) PL IRR diet; Special Diet Service) with free access to food and water. All animals were six to ten weeks of age at the start of the experiment. All NS3/4A-Tg mice were genotyped by PCR to verify the transgene. Extraction of DNA from the tail was performed using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions, and the NS3/4A transgene and the reference gene tubulin were amplified by PCR. All experimental protocols involving animals were approved by the Ethical Committee for Animal Research at Karolinska Institutet. The methods were carried out in accordance with the approved guidelines.
Plasmid DNA
The codon-optimized (co) NS3/4A-pVAX1 genotype 1a plasmid (GenBank accession number: ncbi-n:AR820945.1; http://www. nbci.nlm.nih.gov/genbank) has been described previously [30, 35] . In addition, five codon-optimized fusion constructs of NS3/4A and stork HBcAg (co-Stork-HBcAg) were made synthetically (Retrogen, San Diego, CA and Genscript, Piscataway, NJ) and inserted into the pVAX1 vector (Invitrogen, Carlsbad, CA) (Fig. 1c) . The five separate fusion constructs were made with the following modifications: C2.1 (GenBank accession number: ncbi-n:GZ869905.1), a coNS3/4A-coStork-HBcAg fusion construct (active protease) containing an NS3-NS4A cleavage site between NS3 and NS4A and an NS4A-NS4B cleavage site between NS4A and stork-HBcAg. NS3, NS4A, and stork-HBcAg are separated by NS3/4A proteolytic cleavage. The C2.3 construct (GenBank accession number: ncbin:GZ869907.1) is identical to C2.1 but with an inactive "mutated" HCV NS3 protease and the NS3-NS4A and NS4A-NS4B cleavage sites have been replaced with 2A self-cleaving peptide sequences. The C2.2 (GenBank accession number: ncbi-n:GZ869906.1), C2.4 (GenBank accession number: ncbi-n:GZ869908.1), and C2.5 (GenBank accession number: ncbi-n:GZ869909.1) constructs are identical to C2.1 and C.2.3, but contain coStork-HBcAg modifications consisting of the introduction of three NS3-NS4A cleavage sites (C2.2 and C2.5, e.g. constructs contain an active protease) or 2A selfcleaving peptide sites (C2.4, e.g. has an inactive "mutated" HCV NS3 protease) in the coStork-HBcAg gene sequence, allowing the expressed NS3/4A protease or the 2A peptide to cleave the modified Stork-HBcAg into four parts (Stork-HBcAg: aa 1-66, aa 67-132, aa 133-198, and aa 199-264). In the C2.5 construct the orientation of the Stork-HBcAg is as follows: aa 199-264, aa 133-198, aa 1-66, and aa 67-132. The C8 construct (GenBank accession number: ncbi-n:GZ869918.1) is identical to the C2.5 but contain human HBcAg as described previously [26] . Additional constructs used within this study; wtNS3-pVAX1 [35] (GenBank accession number: ncbi-p:AFS93973.1), wtNS3/4A pVAX1 [30, 35] (GenBank accession number: ncbi-n:GZ869870.1), coHBcAg-pVAX1 [28, 36] (GenBank accession number: ncbi-n:DI244925.1), wt-and co-Stork-HBcAgpVAX1 (GenBank accession number: ncbi-n:GZ869879.1), and wtand co-Heron-HBcAg-pVAX1 (GenBank accession number: ncbin:GZ869880.1).
Mouse interleukin-12 (pORF-mIL-12, mIL-12) was purchased from InvivoGen (San Diego, USA). Plasmids were grown in competent TOP10 Escherichia coli (Life Technologies, Carlsbad, CA) and purified using Qiagen EndoFree Plasmid purification Kit according to the manufacturer's instructions (Qiagen, Hilden, Germany). Plasmid DNA concentration was determined spectrophotometrically and the purified DNA was dissolved in sterile PBS at concentrations of 2 mg/ml. Restriction enzyme digest were performed to ensure that the plasmid contained the gene of interest with the correct size. All DNA plasmids were sequenced to ensure correct nucleotide sequence (Eurofins MWG Operon, Ebersberg, Germany).
In vitro transcription and translation assay
To confirm expression and proteolytic/self-cleaving activity of the studied constructs an in vitro transcription and translation assay (TNT; Promega, Madison, WI) were employed [30, 37] .
Cell line
HepG2 was maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO), 2 mM l-glutamine, 10 mM HEPES, 100 U ml −1 penicillin, 100 g/ml streptomycin, 1 mM nonessential amino acids, and 1 mM sodium pyruvate (Sigma-Aldrich). The cells were grown in a humidified 37 • C and 5% CO 2 incubator.
Transient transfection, protein sample preparation, immuno-precipitation and Western blot analysis
HepG2 cells were transiently transfected using TurboFect (Fermentas, Leon-Rot, Germany), according to manufacturer's instructions. In brief, 1 × 10 6 cells per 25 cm 2 (e.g. T25) flask were transiently transfected using 4 g plasmid DNA together with 6 l TurboFect in vitro transfection reagent and incubated for 36 h prior to harvest. Cells were harvested and lysed in 1 ml RIPA buffer (0.15 mol/L NaCl containing 50 mmol/L Tris, 1% Triton X-100, 1% Nadeoxycholate, and 1% SDS). Liver biopsies (100 mg) were homogenized using sonication (Vibra Cell Homogenizator; Chemical Instruments, Lidingö, Sweden) in 1 ml RIPA buffer. The liver homogenates were incubated on ice for 10-20 min and centrifuged at 12,000 × g for 2 min at 4 • C, and the supernatant was transferred to a new vial and stored at −80 • C until analysis. The cell and liver lysates were immuno-precipitated with protein-A sepharose and polyclonal mouse anti-NS3 antibody overnight at 4 • C. Samples were diluted in SDS sample buffer, heated at 100 • C for 5 min before SDS-PAGE analysis on 4-12% Bis-Tris gel (Life Technologies, Carlsbad, CA) followed by electrotransfer onto nitrocellulose membranes [56] and HBc141-149 [57] ) and two H-2 b epitopes (HBc93-100 [39] and HBc129-140 [40] ) (a). An "-" indicate epitope sequences homology. Groups of five wild-type C57BL/6J mice were immunized twice intramuscularly with 100 g of Stork-, Heron-or human HBcAg plasmid DNA and anti-HBc IgG titers determined at indicated time-points (b). Also, mice were immunized intramuscularly using wild-type-or codon-optimized Stork-HBcAg plasmids with or without in vivo ET. Groups were compared by serum dilution and measurement of optical density at 450 nm. Design of the coNS3/4A-coHBcAg containing DNA constructs evaluated in the present study (c). The plasmids encode codon-optimized HCV NS3 and NS4A proteins followed by different variants of HBcAg either derived from stork or human. An "empty triangle" indicates a HCV NS3 protease cleavage site whereas a "filled triangle" describes a self-cleaving 2A peptide sequence. In constructs containing self-cleaving sequences the NS3 protease has been inactivated by mutation of amino acids in the catalytic triade. Numbers (e.g. 1-4) indicated in the constructs containing fragmented HBcAg sequences refers to the order of the different fragments in the gene sequence. Individual wild-type (wt) NS3, wtNS3/4A, coNS3/4A, coHBcAg constructs and fusion constructs (C2.1-C2.5) were tested for their expression by an in vitro transcription and translation assay (d), and/or by transient transfection of HepG2 cells (e). NS3-protein expression was determined by immune-precipitation and Western blot (d). M indicates the molecular weight marker, Magic Mark (Life Technologies, Carlsbad, CA). IgH = immunoglobulin heavy chain. using the iBlot (Life Technologies, Carlsbad, CA). NS3-proteins were detected using a polyclonal mouse anti-NS3 antibody (diluted 1:100). Chemiluminescence-linked Western blot kit (WesternBreeze WB7104, anti-mouse; Life Technologies, Carlsbad, CA) was used for the detection of NS3 according to the manufacturer's protocol. Chemiluminescent signals were detected using the G:BOX Chemi XX6 gel documentation system (Syngene, Cambridge, UK).
Peptides and proteins
A total of 135 15-mer peptides (each having 10 amino acid (aa) overlap) covering the full-length HCV NS3 and NS4A genotype 1a protein were purchased from Sigma-Aldrich (St. Louis, MO). The 135 peptides were divided into nine peptide pools as outlined: pool 1 1026-1110 , pool 2 1101-1185 , pool 3 1176-1260 , pool 4 1251-1335 , pool 5 1326-1410 , pool 6 1401-1485 , pool 7 1476-1560 , pool 8 , and pool 9 . In order to perform detailed studies of HCV-and HBV-specific CD4 + and CD8 + T cell responses, previously identified H-2 b -restricted CTL and T helper (Th) epitopes were used: HCV NS3-CTL peptide (H2-D b aa sequence: GAVQNEVTL (NS3 aa 1629-1637)) [35] , HCV NS3-Th peptide (aa sequence: EIPFYGKAIPLEAIK (E13K aa 1372-1386)) [38] , HBcAg-CTL peptide (H-2K b aa sequence: MGLKFRQL (HBcAg aa 93-100)) [39] , and HBcAg-Th peptide (H-2IA b aa sequence: PPAYRPPNAPIL (HBcAg aa 129-140)) [40] . The following non-HBV control peptides were used; SIINFEKL (OVA 257-264, CTL-epitope) and ISQAVHAA-HAEINEAGR (OVA 323-339, Th-epitope) were synthesized by automated peptide synthesis as described previously (ChronTech Pharma AB, Huddinge, Sweden) [41] . Recombinant HCV NS3 protein gt1a (aa 1207-1612) and HBcAg-protein (aa 1-183) were produced in E. coli and purified as described [42] . Chicken egg albumin (OVA) and Concanavalin A (ConA) were purchased from Sigma-Aldrich (St. Louis, MO).
Immunization protocol
Groups (5-10 mice/group) of female C57BL/6J (wt), CD4−/−, CD8−/−, NS3/4A-Tg, and HBeAg-Tg C57BL/6J mice, 6-10 weeks old, were immunized intramuscularly (i.m.) in the tibialis cranialis muscle one to five times with doses of 50, 5, 0.5, 0.05, and 0.005 g plasmid DNA (e.g. coNS3/4A-pVAX1, C8-pVAX1, C2.1-pVAX1, C2.2-pVAX1, C2.3-pVAX1, C2.4, and C2.5-pVAX1) alone or in combination with 5 g mIL-12-pORF1 in a volume of 30 L using the in vivo intracellular injection device (IVIN) [27, 43] or by regular needle injection. Immediately following administration of the plasmid DNA, tibialis cranialis muscles were subsequently electroporated (EP) using the Cliniporator 2 device (IGEA, Carpi, Italy) with a 1 ms 600 V/cm pulse followed by a 400 ms 60 V/cm pulse pattern. Mice were boosted at monthly intervals. A detailed description of the IVIN device, used for delivery of DNA vaccine, is described previously [43] . Analysis of HCV NS3/4A-specific immune responses were performed at two-weeks or six months post last immunization. Determination of HCV NS3-protein expressing liver cells in vivo was performed in groups of immunized and nonimmunized mice. Six months after the last immunization, mice were given a hydrodynamic injection of the coNS3/4A plasmid, exactly as described previously [44] . In brief, a total volume of 1.8 ml (8% of body weight) Ringers solution containing 100 g coNS3/4A-pVAX1 was injected intravenously in the tail vein within 5 s. Presence of HCV NS3-protein expression was determined 72 h later by immune-precipitation and Western blot analysis.
Detection of HBcAg-specific antibodies using ELISA
Serum from immunized C57BL/6J mice were collected at week 2, 4, and 6 via retro-orbital bleeding of Isofluran anesthetized mice. Detection of mouse IgG antibodies to HBcAg was performed as described previously [45] . In brief, plates were coated with 2 g/ml HBcAg protein. Mouse serum was added in serial dilution (starting dilution of 1:50 and then diluted 1:5). OD was read at 405 nm with a 620 nm background. The cutoff value was set to three times the OD value of negative serum sample.
Detection of IFN--and IL-2-producing CTLs and Th cells by ELISpot assay
Splenocytes from groups of mice (5-10 mice/group) were pooled and tested for the presence of NS3/4A-or HBcAg-specific T cells. We assessed the ability of NS3/4A-and HBcAg-specific CTLs and Th cells to produce IFN-␥ and IL-2 after exposure to different peptides and proteins: NS3-CTL gt1a (GAVQNEVTL), NS3-Th E13K gt1a (EIPFYGKAIPLEAIK), HBcAg-CTL (MGLKFRQL), HBcAg-Th (PPAYRPPNAPIL), recombinant HCV NS3 and HBcAg proteins. The following non-HCV and HBV peptides and proteins were included as control antigens: OVA-CTL (SIINFEKL), OVA-Th (ISQAVHAA-HAEINEAGR), and OVA protein (OVA grade VII). Concanavalin A was used as a positive control and DMSO at the same concentration as in the peptide pools were used as a negative control and/or medium alone. Production of IFN-␥ and IL-2 cytokines was determined by a commercially available ELISpot assay (Mabtech, Nacka Strand, Sweden) exactly as described previously [46] . The number of spots was counted using the AID iSpot reader and software version 7.0 (AID, Strassberg, Germany). The number of spots (cytokine producing cells) was determined at each concentration of peptide or protein and the results given as the number of IFN-␥ or IL-2-producing cells per 10 6 cells. A mean number of cytokine producing cells of 50 per 10 6 cells were considered as negative.
Quantification of HCV NS3-and HBcAg-specific CD8 + T cells by pentamer staining
The frequency of NS3-and HBcAg-specific CD8 + T cells was analyzed by direct ex vivo staining of splenocytes using the NS3 GAVQNEVTL (H2-D b ) and HBcAg MGLKFRQL (H-2K b ) Pro5 pentamers (ProImmune, Oxford, U.K.) performed exactly as described previously [26] . The following antibodies were used: anti-mouse CD16/32 "Fc block", anti-mouse CD19-APC "clone 1D3" (BD Biosciences, San Jose, CA), anti-mouse CD8-FITC "clone KT15" (ProImmune). A total of 150,000 total events from each sample were acquired on a FACSCalibur or FACSVerse flow cytometer (BD Biosciences) and analyzed using the CellQuest (San Jose, CA) or FlowJo 9.2 software (Ashland, OR).
Statistical analysis
All comparisons were performed using GraphPad InStat 3, Macintosh (version 3.0b, 2003; GraphPad Software, San Diego, CA) and Microsoft Excel 2011, Macintosh (version 14.3.9; Microsoft, Redmond, WA). Kinetic measurements were compared using the area under the curve (AUC, Excel). Parametrical data were compared using the analysis of variance (ANOVA) and non-parametrical data with Mann-Whitney U test. Frequencies were compared using Fisher's exact test.
Results
Immunogenicity of heron and stork HBcAg genes
We have previously shown that inclusion of the human hepatitis B virus core antigen (HBcAg) improves the immunogenicity of HCV NS3/4A-based genetic vaccines [26] . As HBV is a common virus and many individuals may have a pre-existing immunity to HBV antigens, including HBcAg, HBV sequences from another species should be safer [47] . In particular avian hepadnaviruses, such as the duck (DHBV), heron (HHBV), and stork (STHBV) hepatitis B virus are genetically distant from human HBV [48] . Amino acid sequence alignment of full-length stork and human HBcAg proteins revealed less than 40% sequence homologue. A detailed analysis of two published HLA-A2.1 epitopes and two H-2 b epitopes further indicate no evident epitope sequence homology between stork and human HBcAg (Fig. 1a) .
We first evaluated the intrinsic immunogenicity of wild-type HBcAg sequences from heron and stork (Fig. 1b) . Both heron and stork HBcAg DNA plasmids induced similar levels of antigenspecific IgG antibodies as human HBcAg (Fig. 1b) . We then tested whether the immunogenicity of stork HBcAg-DNA could be improved by codon-optimization (co) and in vivo electro transfer (ET; Fig. 1b ). Both these parameters clearly improved immunogenicity (Fig. 1b) .
Generation of NS3/4A and stork HBcAg fusion genes
We now wanted to test if we could transfer the potent immunogenicity of stork HBcAg to function as an adjuvant for HCV NS3/4A, as we previously found that human HBcAg could [26] . To understand the adjuvant effect of stork HBcAg on HCV NS3/4A we designed and tested constructs with the same design as previously evaluated using human HBcAg and HCV NS3/4A [26] . We generated fusion genes expressing HCV NS3/4A and full-length or fragmented stork HBcAg proteins (Fig. 1c) . The fragmented HBcAg sequences contained either NS3/4A cleavage sites or self-cleaving 2A peptide sequences between and/or within the expressed proteins (Fig. 1c ) [49, 50] . The NS3 protease function was abolished in constructs containing self-cleaving 2A peptide sequences by point mutations in the NS3 catalytic triad. A HCV NS3/4A construct containing human HBcAg (e.g. C8) was included as a control for comparison with constructs containing stork HBcAg. All fusion constructs had the expected size and cleavage pattern evidenced by results from an in vitro transcription and translation assay (Fig. 1d) . As shown previously in the in vitro transcription and translation assay, the cleavage at NS3/4A junction sites was not complete whereby uncleaved products are also visualized (Fig. 1d) [26, 37] . On the other side, constructs containing 2A self-cleaving peptide sequences had an almost complete cleavage of NS3-NS4A and stork HBcAg shown by only a NS3 protein band and the absence of an NS3-NS4A fusion protein (Fig. 1d) .
We next analyzed the expression of all fusion constructs by transient transfection and Western blot analysis. From previous experience we know that the NS3-NS4A cleavage is close to 100% effective, which is clearly shown in Fig. 1e where all NS3 or NS3/4A-containing constructs shows only protein bands corresponding to the NS3 protein. Hence, all generated fusion constructs were expressed and processed to the expected proteins.
3.3.
Fragmented stork HBcAg-sequences adjuvant priming of potent NS3/4A-specific T cell responses in wild-type-and NS3/4A-Tg mice
We next evaluated if we could improve the vaccine immunogenicity of our previously designed vaccine composed of a NS3/4A gene fused with human HBcAg (e.g. C8, Fig. 1c ) [26] by inclusion of murine (m) IL-12. We have previously shown that mIL-12 improved the HBV-specific T cell response after DNA-based immunization [27] . The addition of mIL-12 significantly improved the induction of IFN-␥-production in immunized NS3/4A-Tg mice and should therefore be considered for inclusion in the vaccine composition (Fig. 2a , p < 0.001 (NS3-CTL and human HBcAg), area under the curve [AUC] and analysis of variance [ANOVA]). Thereafter, five NS3/4A and stork or human HBcAg [48] fusion plasmids were evaluated in combination with mIL-12, delivered using the IVIN device followed by in vivo ET, in wild-type-and NS3/4A-Tg mice to identify the most immunogenic plasmid (Fig. 2b and c, and Supplementary Fig. 1a ). As the "golden standard", we used the C8 plasmid (Figs. 1c, 2a-c , and Supplementary Fig. 1a) . In both wild-type-and NS3/4A-Tg mice, the NS3/4A constructs with active protease and a fragmented stork HBcAg (C2.2) induced the strongest immune responses determined by IFN-␥-and IL2-production (Fig. 2a-c , and Supplementary  Fig. 1a , p < 0.001 (NS3-CTL), AUC and ANOVA). Importantly, the use of stork HBcAg even exceeded the immune activation to human HBcAg (e.g. C8, p < 0.001 (NS3-CTL), AUC and ANOVA). Consistent with previous data [26] , the priming of T cells in NS3/4A-Tg mice was less efficient due to the dysfunctional T cell response to NS3/4A (Fig. 2c, and Supplementary Fig. 1b and c) . This supports the importance of the NS3/4A-Tg mouse model to dissect differences in immunogenicity between NS3/4A-based vaccines. Quantification of NS3-specific CD8 + T-cells revealed similar frequencies of T cells in wild-type mice regardless of the vaccine ( Supplementary Fig.  1b and c, p = NS, Mann-Whitney U test). A single immunization induced borderline levels of NS3-specific CD8 + T-cells determined by pentamer staining in the NS3/4A-Tg mice ( Supplementary Fig.  1b and c) . Representative flow cytometry dot plots have been shown (Supplementary Fig. 1c) . We have previously shown that the induction of low levels of NS3-specific CD8 + T-cells in the NS3/4A-Tg mice requires at least two immunizations [26] .
Co-expression of murine IL-12 improves immunogenicity to NS3/4A
As mentioned in the previous section, one additional way to improve immunogenicity of genetic vaccines is the inclusion of genetic adjuvants such as plasmids expressing cytokine genes for example murine (m) IL-12 [27] . We therefore tested whether the addition of a mIL-12-expressing plasmid may act as an adjuvant for the vaccines containing NS3/4A and stork HBcAg (C2.2 and C2.5; Fig. 1c ). Mice were immunized intramuscularly once with 0.005, 0.05, 0.5, and 5 g of the NS3/4A-based plasmid containing stork HBcAg (C2.2), with or without, 5 g mIL-12 plasmid using the in vivo intracellular injection (IVIN) device followed by in vivo electro transfer (ET; Fig. 3a) . The addition of IL-12 improved the NS3-specific T cell response regardless of C2.2 vaccine dose (Fig. 3a , p < 0.001 (NS3-CTL and E13K), AUC and ANOVA). Thus, addition of IL-12 allowed for C2.2 vaccine doses as low as 0.05 g plasmid DNA per dose resulting in detectable immune responses to NS3. Because the vaccine is intended for human it is crucial that we develop a vaccine that is highly immunogenic also at low vaccine doses, making it possible to translate the mouse vaccine dose into a realistic human vaccine dose. Our data show that addition of IL-12 can help retain the immunogenicity also at lower vaccine doses, which is important when moving from smaller to larger animals and humans. To test if this could be translated to other NS3/4A and stork HBcAg genes, groups of wild-type mice were immunized intramuscularly once with 0.5 g of either the C2.2 or C2.5 plasmid, together with 5 g mIL-12 using the IVIN device (Fig. 3b) . Also the C2.5 plasmid was highly immunogenic at the low 0.5 g dose in combination with mIL-12 (Fig. 3b , p < 0.001 (NS3-CTL), and p < 0.01 (E13K), AUC and ANOVA). Thus, the plasmid encoding mIL-12 was therefore included in all further experiments.
Priming of NS3/4A-specific T cells in a host with dysfunctional HBV-specific T cells
HBV is a common virus globally. One can therefore argue whether the use of gene sequences from human HBV as carrier molecules or adjuvants is advisable. Safety is one reason to use non-human HBV sequences as adjuvants. We therefore immunized HBeAg-Tg mice with a partially dysfunctional T cell response to HBcAg and HBeAg [27, 33] with plasmids containing NS3/4A and stork or human HBcAg (C2.2 and C8, respectively) or only human HBcAg. A single dose of NS3/4A and stork HBcAg seemed to prime lower levels of NS3/4A-specific IFN-␥-and IL-2 in HBeAg-Tg mice as compared to previous experiments in wild-type mice (Fig. 4a,  Supplementary Fig. 2 , and data not shown). Interestingly, the stork containing NS3/4A plasmid primed significantly stronger IFN-␥-producing CTLs compared to the same plasmid containing human HBcAg (p < 0.05, AUC and ANOVA). As expected, similar levels of NS3-specific CTLs were detected in C2.2 and C8 immunized wild-type-and HBeAg-Tg mice (Fig. 4b and data not shown) . Importantly, the NS3/4A-stork HBcAg vaccine (C2.2) induced significantly lower levels of CTLs specific for human HBcAg, than human HBcAg alone (Fig. 4c) . This is an important safety aspect when vaccinating against HCV in HBV infected individuals. Hence, as predicted the use of stork HBcAg in the C2.2 plasmid avoided a strong immune activation to human HBV in the HBeAg-Tg mice.
Boosting effect of repeated immunization of NS3/4A containing stork HBcAg
We next investigated whether repeated immunization using the plasmid containing NS3/4A and stork HBcAg construct (C2.2) had a booster effect. This is important because when the vaccine is given to humans multiple doses will be needed for activation of strong vaccine antigen-specific immune responses. Repeated immunizations will also answer whether a disadvantageous antivector immune response is primed that will rapidly clear the vaccine-antigen production at the site of immunization and subsequently result in a suboptimal booster effect. Immune responses were determined after one to five immunizations in wild-typeand NS3/4A-Tg mice. Wild-type-and NS3/4A-Tg mice were immunized with 5 or 50 g plasmid, in combination with 5 g mIL-12 plasmid, using the IVIN device and in vivo ET. Repeated immunizations using either vaccine dose significantly boosted both the breadth and magnitude of the NS3-specific T cell responses in wild-type-and NS3/4A-Tg mice (Fig. 5a-c, and Supplementary Fig.  3a -c, p < 0.001, p < 0.01, and p < 0.05, AUC and ANOVA). In particular the NS3-specific IL-2 responses were effectively boosted in the wild-type mice (Fig. 5b, and Supplementary Fig. 3b ). The use of a higher vaccine dose (e.g. 50 g) seemed to prime stronger immune responses in the NS3/4A-Tg mice (Fig. 5c , and Supplementary Fig. 3c) . Thus, NS3-specific T cell responses are boosted by repeat immunizations in both wild-type-and NS3/4A-Tg mice.
NS3/4A with stork HBcAg induces durable in vivo functional immune responses
To understand the duration of the primed immune responses [30, 46] and key factors supporting durability, we immunized wildtype, CD4−/−, and CD8−/− mice thrice with C2.2 in combination with mIL-12, using the IVIN device and in vivo ET. Long-term durability of vaccine-primed immune responses is particularly important for a prophylactic HCV vaccine. Here, vaccinated individuals should be protected even though exposed to infection at a later occasion. Of course, also in the case of a therapeutic vaccine the durability of the primed immune response should be retained post-cure to reduce the risk of re-infection, but most importantly be able to rapidly mediate clearance of the infected cells. We showed that NS3-specific immune responses remain detectable at six months after the third vaccination only in wild-type, and not in CD4−/− or CD8−/− mice (Fig. 6a, and Supplementary Fig.  4 , p < 0.001, AUC and ANOVA). Albeit the responses had reduced as compared to two weeks after three immunizations (Figs. 5a and 6a ), they were still fully functional in vivo (Fig. 6b) . This is of importance in a prophylactic setting and in patients with a dysfunctional T cell response [18] [19] [20] 23] . Thus, although CD4 + T cells may not be pivotal during the priming of NS3-specific CTLs [51] , they are absolutely pivotal for the maintenance of the responses.
Discussion
Molecular adjuvants are often key components to improve immunogenicity of vaccines. With respect to genetic vaccines, it is optimal if the adjuvant can be produced at the same time as the vaccine itself. Importantly, the adjuvant should be present in the same cell as the vaccine to fully utilize its effects. Thus, in genetic vaccines it is to be preferred that the adjuvant can be included in the same expression vector as the vaccine genes.
It has previously been shown that human HBcAg can act as an adjuvant for inserted sequences in the loop region (e.g. at the tip of the spike) of HBcAg when expressed as a recombinant protein [52] [53] [54] . HBcAg has been shown to have some unique properties when used as a vaccine carrier or adjuvant. Hence, HBcAg is presented effectively through B-cells, which become activated through crosslinking of surface receptors [55] . In addition, HBcAg binds RNA, which activates toll-like receptor (TLR)-7 signaling [55] . Thus, these properties make HBcAg an attractive adjuvant. We have shown that HBcAg can be made highly immunogenic as a genetic immunogen, and that human HBcAg can act as an adjuvant in genetic vaccines [26] . However, there are concerns when using human HBcAg as an adjuvant due to the fact that HBV is a common virus. In particular, the presence of a tolerized HBV-specific immune response, or the activation of an HBV-specific immune response in a HBV carrier may have undesired and unexpected effects. This may hold true particularly when used in genetic immunogens that effectively induce CTLs, which may efficiently eradicate HBV infected hepatocytes and thereby cause fulminant hepatitis. Thus, it is important to use safer adjuvants. This is where non-human, or avian, HBcAg sequences come into play.
We have shown that human HBcAg act as a genetic adjuvant, in particular in supporting activation of NS3-specific T cell responses in a host with a dysfunctional T cell response to HCV [26] . We recently showed that human HBcAg could be made highly immunogenic on its own with the addition of mIL-12 [27] . We here wanted to extend these two observations to a completely new adjuvant system.
We found that human, heron and stork HBcAg have a similar intrinsic immunogenicity as DNA vaccines. Notably, they do not share the same HLA/MHC class I and II epitope sequences, which minimizes the risk of cross-reactivity between individuals previously exposed to human HBV and possible recipients of a genetic vaccine including stork HBcAg as adjuvant. This is further strengthen by the fact that full-length human and avian HBcAg show less than 40% amino acid sequence homology [48] . Importantly, we could show that the immunogenicity of stork HBcAg could be further improved by the addition of mIL-12 and was done in immunized and non-immunized NS3/4A-transgenic (a and c) and wild-type C57BL/6J (b) mice. As control antigens OVA-CTL (a; 1 g/ml, b and c; 10 g/ml), OVA-Th (1 g/ml), OVA-protein (10 g/ml), and ConA (a; 2, 1, 0.5 g/ml, b and c; 2, 1, 0.5, 0.1 g/ml) were used. Deescalating doses are represented by triangles (each bar represents a specific concentration). Results are given as the mean SFCs/10 6 (+SD) with a cut-off set at 50 SFCs/10 6 splenocytes. The statistical difference shown, indicate a group that is significantly different from all other groups (***p < 0.001, by comparing area under the curve (AUC) and analysis of variance (ANOVA)). Fig. 3 . Co-administration of NS3/4A and IL-12 enhances the NS3-specific immune response. Groups of five wild-type C57BL/6J mice were immunized once with 0.005, 0.05, 0.5 and 5 g C2.2-pVAX1 plasmid DNA with or without 5 g mIL-12-pORF1 plasmid DNA in a volume of 30 L using IVIN followed by in vivo ET (a). One group of mice were left untreated (data not shown). Two weeks after immunization the mice were sacrificed and splenocytes harvested for determination of T cell responses. We compared the number of IFN-␥ SFCs by ELISpot assay after stimulation with deescalating doses of the following antigens: a CTL peptide (NS3-CTL, 0.25, 0.025, 0.0025, 0.00025, 0.000025, 0.0000025, 0.00000025, 0.000000025 g/ml), a Th peptide (E13K, 10, 1, 0.1, 0.01, 0.001 g/ml) or 9 peptide pools covering the full-length NS3 and NS4A proteins (10, 1 g/ml). As control antigens OVA-CTL (1 g/ml), OVA-Th (1 g/ml), and ConA (1, 0.5 g/ml) were used. Deescalating doses are represented by triangles (each bar represents a specific concentration). (b) Shows the number of IFN-␥ SFCs in groups of mice immunized once with 0.5 g C2.2-pVAX or C2.5-pVAX1 in combination with 5 g mIL-12-pORF1. Deescalating doses of exactly the same antigens as described in (a) were used for stimulation, except that we only used one concentration of the 9 peptide pools (10 g/ml). Results are given as the mean SFCs/10 6 (+SD) with a cut-off set at 50 SFCs/10 6 splenocytes. The statistical difference between the groups is indicated as **p < 0.01 and ***p < 0.001, area under the curve (AUC) and analysis of variance (ANOVA). or recombinant proteins (rNS3; 10, 2, 0.4, 0.8, 0.016 g/ml, rHBc; 10, 1, 0.1 g/ml) was determined by ELISpot assay. As control antigens OVA-CTL (1 g/ml), OVA-Th (1 g/ml), OVA-protein (10 g/ml), and ConA (1, 0.5 g/ml) were used. Deescalating doses are represented by triangles (each bar represents a specific concentration). Results are given as the mean SFCs/10 6 (+SD) with a cut-off set at 50 SFCs/10 6 splenocytes. Statistical differences have been indicated when one group of mice had significantly higher levels compared to all other groups (*p < 0.05, using area under the curve (AUC) and analysis of variance (ANOVA)). The expansion of NS3-specific (b) and HBcAg-specific (c) CD8
a) b)
+ T cells in HBeAg-transgenic mice was determined using direct ex vivo pentamer staining. GAVQNEVTL or MGLKFRQL epitope-specific CD8 + T cells are shown as the percentage of NS3-or HBcAg-pentamer positive CD8 + T cells where each filled black circle represent an individual mouse. The black horizontal line indicates the mean of the group. The statistical difference between the groups is indicated as *p < 0.05 and **p < 0.01 determined by the Mann-Whitney U test.
delivery by IVIN and in vivo ET. This enhanced immunogenicity could then be effectively transferred to HCV NS3/4A in various fusion constructs. Notably, we found that fragmented stork HBcAg more efficiently improved T cell priming to HCV NS3/4A than fulllength stork HBcAg. Hence, this may be a general aspect of HBcAg regardless of the species as this also applied to human HBcAg [26] . This is possibly explained by the fact that HBcAg may provide heterologous T cell help at the site of immunization and/or in local lymphnodes thereby enhancing the priming of HCV-specific T cell responses. However, the exact mechanism/s how stork To evaluate the longevity of NS3-specific immune responses groups of 8-10 wild-type C57BL/6J, CD4−/− and CD8−/− mice were immunized thrice at monthly intervals with 50 g C2.2-pVAX1 in combination with 5 g mIL-12-pORF1 in a volume of 30 L using IVIN followed by in vivo ET. Also, groups of five wild-type C57BL/6J, CD4−/− and CD8−/− mice were left untreated. Six months after the last immunization, mice were challenged using a hydrodynamic injection of 100 g coNS3/4A-pVAX1. 72 h later mice were sacrificed and splenocytes harvested for determination of IFN-␥ responses (a) and livers for presence of hepatic NS3-protein in immunized and non-immunized groups (b). We compared the number of IFN-␥ SFCs by ELISpot assay after stimulation with the following antigens: a CTL peptide (NS3-CTL, 0.25, 0.025, 0.0025, 0.00025, 0.000025, 0.0000025 g/ml), a Th peptide (E13K, 10, 1 g/ml) or 9 peptide pools covering the full-length NS3 and NS4A proteins (10, 1 g/ml). As control antigen ConA (2, 1 g/ml) was used. Deescalating doses are represented by triangles (each bar represents a specific concentration). Results are given as the mean SFCs/10 6 (+SD) with a cut-off set at 50 SFCs/10 6 splenocytes. Statistical differences have been evaluated among groups of immunized mice and between immunized and non-immunized mice (***p < 0.001 using area under the curve (AUC) and analysis of variance (ANOVA), nonimmunized groups are shown in Supplementary Fig. 4) . In vivo clearance of transient hepatic NS3-protein expression was analyzed by immune-precipitation and Western blot 72 h after the hydrodynamic injection in groups of immunized-and non-immunized wild-type-and CD4 and CD8 knockout mice (b). A "+" indicate positive control (e.g. coNS3/4A transiently transfected HepG2 cells), and a "−" indicate the negative control (e.g. mock transfected HepG2 cells). The number and percentage of NS3-positive mice per group is indicated above each gel. The gels show only representative results from each group and additional data is included as data not shown. Statistical differences have been evaluated among groups of immunized and non-immunized mice (**p < 0.01 using Fischer's exact test). NS = not significant.
HBcAg enhances the HCV NS3/4A-specific T cell response has to be determined. The HCV NS3/4A and stork HBcAg-based vaccines effectively primed HCV-specific CTLs without an effective induction of CTLs specific for human HBcAg. This is an essential safety aspect of any adjuvant system utilizing sequences from human pathogens.
The immunogenicity of the HCV NS3/4A and stork HBcAgbased vaccines could be boosted by giving additional monthly vaccination. In particular the IL-2 producing T-helper cell responses improved after boosting, which is essential for T cell expansion and memory development. We could show that three doses of the C2.2 vaccine resulted in in vivo functional T cell responses that lasted for at least six months. This aspect is essential in a prophylactic setting, where a T cell based vaccine should rapidly mediate clearance of the invading virus.
In conclusion, we here show that avian HBcAg sequences effectively and safely can be applied to genetic vaccines as molecular adjuvants encoded by the same plasmid as the vaccine. This simplifies vaccine development. In addition, we have also shown that this adjuvant effect can be applied to other viral vaccines (Holmström et al., accepted for publication in Scientific Reports). Thus, avian HBcAg can effectively be applied as a general adjuvant in genetic vaccines.
antigens OVA-CTL (1 g/ml), OVA-Th (1 g/ml), OVA-protein (10 g/ml), and ConA (2, 1, 0.5, 0.1 g/ml) were used. Deescalating doses are represented by triangles (each bar represents a specific concentration). Results are given as the mean SFCs/10 6 (+SD) splenocytes with a cut-off set at 50 SFCs/10 6 splenocytes. Statistical analysis has been done by comparing if 2, 3, 4 and 5 immunizations improved immune responses as compared to a single immunization (*p < 0.05, **p < 0.01 and ***p < 0.001 using area under the curve (AUC) and analysis of variance (ANOVA)).
